Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 313

1.

Dulaglutide slows kidney disease in type 2 diabetes - Author's reply.

Gerstein HC.

Lancet. 2020 Feb 22;395(10224):559-560. doi: 10.1016/S0140-6736(19)32541-3. No abstract available.

PMID:
32087783
2.

Influence of Genetic Ancestry on Human Serum Proteome.

Sjaarda J, Gerstein HC, Kutalik Z, Mohammadi-Shemirani P, Pigeyre M, Hess S, Paré G.

Am J Hum Genet. 2020 Feb 7. pii: S0002-9297(20)30016-1. doi: 10.1016/j.ajhg.2020.01.016. [Epub ahead of print]

PMID:
32059761
3.

Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions.

Sharma A, Pagidipati NJ, Califf RM, McGuire DK, Green JB, Demets D, George JT, Gerstein HC, Hobbs T, Holman RR, Lawson FC, Leiter LA, Pfeffer MA, Reusch J, Riesmeyer JS, Roe MT, Rosenberg Y, Temple R, Wiviott SD, McMurray JJV, Granger CB.

Circulation. 2020 Jan 29. doi: 10.1161/CIRCULATIONAHA.119.041022. [Epub ahead of print]

PMID:
31992065
4.

A PPARA Polymorphism Influences the Cardiovascular Benefit of Fenofibrate in Type 2 Diabetes: Findings From ACCORD Lipid.

Morieri ML, Shah HS, Sjaarda J, Lenzini PA, Campbell H, Motsinger-Reif AA, Gao H, Lovato L, Prudente S, Pandolfi A, Pezzolesi MG, Sigal RJ, Paré G, Marcovina SM, Rotroff DM, Patorno E, Mercuri L, Trischitta V, Chew EY, Kraft P, Buse JB, Wagner MJ, Cresci S, Gerstein HC, Ginsberg HN, Mychaleckyj JC, Doria A.

Diabetes. 2020 Jan 23. pii: db190973. doi: 10.2337/db19-0973. [Epub ahead of print]

PMID:
31974142
5.

The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial.

Gerstein HC, Hart R, Colhoun HM, Diaz R, Lakshmanan M, Botros FT, Probstfield J, Riddle MC, Rydén L, Atisso CM, Dyal L, Hall S, Avezum A, Basile J, Conget I, Cushman WC, Hancu N, Hanefeld M, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Muñoz EGC, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T.

Lancet Diabetes Endocrinol. 2020 Feb;8(2):106-114. doi: 10.1016/S2213-8587(19)30423-1. Epub 2020 Jan 7.

PMID:
31924562
6.

Are large simple trials for dementia prevention possible?

Whiteley WN, Anand S, Bangdiwala SI, Bosch J, Canavan M, Chertkow H, Gerstein HC, Gorelick P, O'Donnell M, Paré G, Pigeyre M, Seshadri S, Sharma M, Smith EE, Williamson J, Cukierman-Yaffe T, Hart RG, Yusuf S.

Age Ageing. 2019 Dec 12. pii: afz152. doi: 10.1093/ageing/afz152. [Epub ahead of print]

PMID:
31830268
7.

Novel Biomarkers for Change in Renal Function in People With Dysglycemia.

Gerstein HC, Paré G, McQueen MJ, Lee SF, Bangdiwala SI, Kannt A, Hess S; ORIGIN Trial Investigators.

Diabetes Care. 2020 Feb;43(2):433-439. doi: 10.2337/dc19-1604. Epub 2019 Nov 14.

PMID:
31727687
8.

Childhood Pancreatitis and Risk for Incident Diabetes in Adulthood.

Bendor CD, Bardugo A, Zucker I, Cukierman-Yaffe T, Lutski M, Derazne E, Shohat T, Mosenzon O, Tzur D, Sapir A, Pinhas-Hamiel O, Kibbey RG, Raz I, Afek A, Gerstein HC, Tirosh A, Twig G.

Diabetes Care. 2020 Jan;43(1):145-151. doi: 10.2337/dc19-1562. Epub 2019 Nov 6.

PMID:
31694859
9.

Diabetes Care Editors' Expert Forum 2018: Managing Big Data for Diabetes Research and Care.

Riddle MC, Blonde L, Gerstein HC, Gregg EW, Holman RR, Lachin JM, Nichols GA, Turchin A, Cefalu WT.

Diabetes Care. 2019 Jun;42(6):1136-1146. doi: 10.2337/dci19-0020.

PMID:
31666233
10.

The importance of randomised vs non-randomised trials - Authors' reply.

Gerstein HC, McMurray J, Holman RR.

Lancet. 2019 Aug 24;394(10199):635. doi: 10.1016/S0140-6736(19)31111-0. No abstract available.

PMID:
31448734
11.

The Cardiovascular Legacy of Good Glycemic Control: Clues About Mediators From the DCCT/EDIC Study.

Riddle MC, Gerstein HC.

Diabetes Care. 2019 Jul;42(7):1159-1161. doi: 10.2337/dci19-0023. No abstract available.

PMID:
31221692
12.

Novel Drug Targets for Ischemic Stroke Identified Through Mendelian Randomization Analysis of the Blood Proteome.

Chong M, Sjaarda J, Pigeyre M, Mohammadi-Shemirani P, Lali R, Shoamanesh A, Gerstein HC, Paré G.

Circulation. 2019 Sep 9;140(10):819-830. doi: 10.1161/CIRCULATIONAHA.119.040180. Epub 2019 Jun 18.

PMID:
31208196
13.

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.

Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T; REWIND Investigators.

Lancet. 2019 Jul 13;394(10193):121-130. doi: 10.1016/S0140-6736(19)31149-3. Epub 2019 Jun 9.

PMID:
31189511
14.

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.

Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Botros FT, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T; REWIND Investigators.

Lancet. 2019 Jul 13;394(10193):131-138. doi: 10.1016/S0140-6736(19)31150-X. Epub 2019 Jun 9.

PMID:
31189509
15.

Vascular Regenerative Cell Exhaustion in Diabetes: Translational Opportunities to Mitigate Cardiometabolic Risk.

Terenzi DC, Trac JZ, Teoh H, Gerstein HC, Bhatt DL, Al-Omran M, Verma S, Hess DA.

Trends Mol Med. 2019 Jul;25(7):640-655. doi: 10.1016/j.molmed.2019.03.006. Epub 2019 Apr 30. Review.

PMID:
31053416
16.

Dysglycemia and the Density of the Coronary Vasa Vasorum.

Gerstein HC, Nair V, Chaube R, Stoute H, Werstuck G.

Diabetes Care. 2019 May;42(5):980-982. doi: 10.2337/dc18-2483. Epub 2019 Mar 12.

PMID:
30862652
17.

Effects of basal insulin glargine and omega-3 on lower limb arterial disease outcome in patients with dysglycaemia: An analysis of the Outcome Reduction with an Initial Glargine INtervention (ORIGIN) trial.

Dagenais GR, Jung H, Bogaty P, Bosch J, Yusuf S, Gerstein HC.

Diabetes Obes Metab. 2019 Jun;21(6):1502-1505. doi: 10.1111/dom.13674. Epub 2019 Mar 20.

PMID:
30785660
18.

Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States.

Boye KS, Riddle MC, Gerstein HC, Mody R, Garcia-Perez LE, Karanikas CA, Lage MJ, Riesmeyer JS, Lakshmanan MC.

Diabetes Obes Metab. 2019 Jun;21(6):1299-1304. doi: 10.1111/dom.13649. Epub 2019 Mar 12.

19.

Real-world studies no substitute for RCTs in establishing efficacy.

Gerstein HC, McMurray J, Holman RR.

Lancet. 2019 Jan 19;393(10168):210-211. doi: 10.1016/S0140-6736(18)32840-X. No abstract available.

PMID:
30663582
20.

Retinopathy, Neuropathy, and Subsequent Cardiovascular Events in Patients with Type 2 Diabetes and Acute Coronary Syndrome in the ELIXA: The Importance of Disease Duration.

Seferovic JP, Bentley-Lewis R, Claggett B, Diaz R, Gerstein HC, Køber LV, Lawson FC, Lewis EF, Maggioni AP, McMurray JJV, Probstfield JL, Riddle MC, Solomon SD, Tardif JC, Pfeffer MA.

J Diabetes Res. 2018 Dec 16;2018:1631263. doi: 10.1155/2018/1631263. eCollection 2018.

21.

The Diabetes Health Coaching Randomized Controlled Trial: Rationale, Design and Baseline Characteristics of Adults Living With Type 2 Diabetes.

Sherifali D, Brozic A, Agema P, Gerstein HC, Punthakee Z, McInnes N, O'Reilly D, Ibrahim S, Usman Ali RM.

Can J Diabetes. 2019 Oct;43(7):477-482. doi: 10.1016/j.jcjd.2018.10.004. Epub 2018 Oct 17.

PMID:
30578164
22.

Testosterone, sex hormone-binding globulin and risk of cardiovascular events: A report from the Outcome Reduction with an Initial Glargine Intervention trial.

Wang A, Arver S, Boman K, Gerstein HC, Fu Lee S, Hess S, Rydén L, Mellbin LG.

Eur J Prev Cardiol. 2019 May;26(8):847-854. doi: 10.1177/2047487318819142. Epub 2018 Dec 19.

PMID:
30567457
23.

Cognitive function in adolescence and the risk for premature diabetes and cardiovascular mortality in adulthood.

Twig G, Tirosh A, Derazne E, Haklai Z, Goldberger N, Afek A, Gerstein HC, Kark JD, Cukierman-Yaffe T.

Cardiovasc Diabetol. 2018 Dec 5;17(1):154. doi: 10.1186/s12933-018-0798-5.

24.

Insulin use for type 2 diabetes: the challenges of predicting trends and modelling care.

Gerstein HC.

Lancet Diabetes Endocrinol. 2019 Jan;7(1):4-5. doi: 10.1016/S2213-8587(18)30312-7. Epub 2018 Nov 21. No abstract available.

PMID:
30470519
25.

Hypoglycemia and Incident Cognitive Dysfunction: A Post Hoc Analysis From the ORIGIN Trial.

Cukierman-Yaffe T, Bosch J, Jung H, Punthakee Z, Gerstein HC.

Diabetes Care. 2019 Jan;42(1):142-147. doi: 10.2337/dc18-0690. Epub 2018 Nov 13.

PMID:
30425095
26.

A Mendelian Randomization-Based Approach to Identify Early and Sensitive Diagnostic Biomarkers of Disease.

Mohammadi-Shemirani P, Sjaarda J, Gerstein HC, Treleaven DJ, Walsh M, Mann JF, McQueen MJ, Hess S, Paré G.

Clin Chem. 2019 Mar;65(3):427-436. doi: 10.1373/clinchem.2018.291104. Epub 2018 Oct 18.

PMID:
30337280
27.

Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical Trial.

Morieri ML, Gao H, Pigeyre M, Shah HS, Sjaarda J, Mendonca C, Hastings T, Buranasupkajorn P, Motsinger-Reif AA, Rotroff DM, Sigal RJ, Marcovina SM, Kraft P, Buse JB, Wagner MJ, Gerstein HC, Mychaleckyj JC, Parè G, Doria A.

Diabetes Care. 2018 Nov;41(11):2404-2413. doi: 10.2337/dc18-0709. Epub 2018 Sep 27.

28.

The association of basal insulin treatment versus standard care with outcomes in anti-GAD positive and negative subjects: A post-hoc analysis of the ORIGIN trial.

Birkeland KI, Grill V, Wium C, McQueen MJ, Lopez-Jaramillo P, Lee SF, Gerstein HC.

Diabetes Obes Metab. 2019 Feb;21(2):429-433. doi: 10.1111/dom.13528. Epub 2018 Oct 3.

PMID:
30203580
29.

Availability and affordability of essential medicines for diabetes across high-income, middle-income, and low-income countries: a prospective epidemiological study.

Chow CK, Ramasundarahettige C, Hu W, AlHabib KF, Avezum A Jr, Cheng X, Chifamba J, Dagenais G, Dans A, Egbujie BA, Gupta R, Iqbal R, Ismail N, Keskinler MV, Khatib R, Kruger L, Kumar R, Lanas F, Lear S, Lopez-Jaramillo P, McKee M, Mohammadifard N, Mohan V, Mony P, Orlandini A, Rosengren A, Vijayakumar K, Wei L, Yeates K, Yusoff K, Yusuf R, Yusufali A, Zatonska K, Zhou Y, Islam S, Corsi D, Rangarajan S, Teo K, Gerstein HC, Yusuf S; PURE investigators.

Lancet Diabetes Endocrinol. 2018 Oct;6(10):798-808. doi: 10.1016/S2213-8587(18)30233-X. Epub 2018 Aug 28.

PMID:
30170949
30.

Minimally important difference and predictors of change in quality of life in type 2 diabetes: A community-based survey in China.

Jin X, Liu GG, Gerstein HC, Levine MAH, Guan H, Li H, Xie F.

Diabetes Metab Res Rev. 2018 Nov;34(8):e3053. doi: 10.1002/dmrr.3053. Epub 2018 Aug 31.

PMID:
30064154
31.

Association of preoperative glucose concentration with myocardial injury and death after non-cardiac surgery (GlucoVISION): a prospective cohort study.

Punthakee Z, Iglesias PP, Alonso-Coello P, Gich I, India I, Malaga G, Jover RD, Gerstein HC, Devereaux PJ.

Lancet Diabetes Endocrinol. 2018 Oct;6(10):790-797. doi: 10.1016/S2213-8587(18)30205-5. Epub 2018 Jul 26.

32.

A1C Targets Should Be Personalized to Maximize Benefits While Limiting Risks.

Riddle MC, Gerstein HC, Holman RR, Inzucchi SE, Zinman B, Zoungas S, Cefalu WT.

Diabetes Care. 2018 Jun;41(6):1121-1124. doi: 10.2337/dci18-0018. No abstract available.

PMID:
29784695
33.

Baseline characteristics and temporal differences in Acarbose Cardiovascular Evaluation (ACE) trial participants.

Theodorakis MJ, Coleman RL, Feng H, Chan J, Chiasson JL, Ge J, Gerstein HC, Huo Y, Lang Z, McMurray JJ, Rydén L, Schröder S, Tendera M, Tuomilehto J, Yang W, Hu D, Pan C, Holman RR; ACE Study Group.

Am Heart J. 2018 May;199:170-175. doi: 10.1016/j.ahj.2017.09.001. Epub 2017 Sep 8. No abstract available.

PMID:
29754657
34.

Item reduction and validation of the Chinese version of diabetes quality-of-life measure (DQOL).

Jin X, Liu GG, Gerstein HC, Levine MAH, Steeves K, Guan H, Li H, Xie F.

Health Qual Life Outcomes. 2018 Apr 27;16(1):78. doi: 10.1186/s12955-018-0905-z.

35.

Newly diagnosed type 2 diabetes may serve as a potential marker for pancreatic cancer.

Dankner R, Freedman LS, Gerstein HC, Roth J, Keinan-Boker L.

Diabetes Metab Res Rev. 2018 Sep;34(6):e3018. doi: 10.1002/dmrr.3018. Epub 2018 Jun 17.

PMID:
29673046
36.

Blood HER2 and Uromodulin as Causal Mediators of CKD.

Sjaarda J, Gerstein HC, Yusuf S, Treleaven D, Walsh M, Mann JFE, Hess S, Paré G.

J Am Soc Nephrol. 2018 Apr;29(4):1326-1335. doi: 10.1681/ASN.2017070812. Epub 2018 Mar 6.

37.

Do sulphonylureas still have a place in clinical practice?

Khunti K, Chatterjee S, Gerstein HC, Zoungas S, Davies MJ.

Lancet Diabetes Endocrinol. 2018 Oct;6(10):821-832. doi: 10.1016/S2213-8587(18)30025-1. Epub 2018 Feb 28. Review.

PMID:
29501322
38.

Cardiovascular Outcomes Trials of Glucose-Lowering Drugs or Strategies in Type 2 Diabetes.

Gerstein HC, Shah R.

Endocrinol Metab Clin North Am. 2018 Mar;47(1):97-116. doi: 10.1016/j.ecl.2017.10.003. Epub 2017 Nov 20. Review.

PMID:
29407059
39.

Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks: Meta-analysis of 10 Trials Involving 77 917 Individuals.

Aung T, Halsey J, Kromhout D, Gerstein HC, Marchioli R, Tavazzi L, Geleijnse JM, Rauch B, Ness A, Galan P, Chew EY, Bosch J, Collins R, Lewington S, Armitage J, Clarke R; Omega-3 Treatment Trialists’ Collaboration.

JAMA Cardiol. 2018 Mar 1;3(3):225-234. doi: 10.1001/jamacardio.2017.5205.

40.

Determinants of cognitive function in individuals with type 2 diabetes mellitus: A meta-analysis.

Mansur RB, Lee Y, Zhou AJ, Carmona NE, Cha DS, Rosenblat JD, Bruins R, Kakar R, Rasgon NL, Lovshin JA, Wroolie TE, Sim K, Brietzke E, Gerstein HC, Rong C, McIntyre RS.

Ann Clin Psychiatry. 2018 Feb;30(1):38-50. Review.

PMID:
29373617
41.

Effect of Basal Insulin Glargine on First and Recurrent Episodes of Heart Failure Hospitalization: The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention).

Gerstein HC, Jung H, Rydén L, Diaz R, Gilbert RE, Yusuf S; ORIGIN Investigators.

Circulation. 2018 Jan 2;137(1):88-90. doi: 10.1161/CIRCULATIONAHA.117.030924. No abstract available.

PMID:
29279340
42.

Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors' Expert Forum.

Cefalu WT, Kaul S, Gerstein HC, Holman RR, Zinman B, Skyler JS, Green JB, Buse JB, Inzucchi SE, Leiter LA, Raz I, Rosenstock J, Riddle MC.

Diabetes Care. 2018 Jan;41(1):14-31. doi: 10.2337/dci17-0057.

43.

Penetrance of Polygenic Obesity Susceptibility Loci across the Body Mass Index Distribution.

Abadi A, Alyass A, Robiou du Pont S, Bolker B, Singh P, Mohan V, Diaz R, Engert JC, Yusuf S, Gerstein HC, Anand SS, Meyre D.

Am J Hum Genet. 2017 Dec 7;101(6):925-938. doi: 10.1016/j.ajhg.2017.10.007.

44.

Modulation of GLP-1 Levels by a Genetic Variant That Regulates the Cardiovascular Effects of Intensive Glycemic Control in ACCORD.

Shah HS, Morieri ML, Marcovina SM, Sigal RJ, Gerstein HC, Wagner MJ, Motsinger-Reif AA, Buse JB, Kraft P, Mychaleckyj JC, Doria A.

Diabetes Care. 2018 Feb;41(2):348-355. doi: 10.2337/dc17-1638. Epub 2017 Nov 28.

45.

Maturation of CGM and Glycemic Measurements Beyond HbA1c-A Turning Point in Research and Clinical Decisions.

Riddle MC, Gerstein HC, Cefalu WT.

Diabetes Care. 2017 Dec;40(12):1611-1613. doi: 10.2337/dci17-0049. No abstract available.

PMID:
29162581
46.

Increases in Natriuretic Peptides Precede Heart Failure Hospitalization in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus.

Wolsk E, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber L, Lawson FC, Lewis EF, Maggioni AP, McMurray JJV, Probstfield JL, Riddle MC, Solomon SD, Tardif JC, Pfeffer MA.

Circulation. 2017 Oct 17;136(16):1560-1562. doi: 10.1161/CIRCULATIONAHA.117.029503. No abstract available.

PMID:
29038210
47.

Optimizing the methodology for measuring supraclavicular skin temperature using infrared thermography; implications for measuring brown adipose tissue activity in humans.

Haq T, Crane JD, Kanji S, Gunn E, Tarnopolsky MA, Gerstein HC, Steinberg GR, Morrison KM.

Sci Rep. 2017 Sep 20;7(1):11934. doi: 10.1038/s41598-017-11537-x.

48.

Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial.

Holman RR, Coleman RL, Chan JCN, Chiasson JL, Feng H, Ge J, Gerstein HC, Gray R, Huo Y, Lang Z, McMurray JJ, Rydén L, Schröder S, Sun Y, Theodorakis MJ, Tendera M, Tucker L, Tuomilehto J, Wei Y, Yang W, Wang D, Hu D, Pan C; ACE Study Group.

Lancet Diabetes Endocrinol. 2017 Nov;5(11):877-886. doi: 10.1016/S2213-8587(17)30309-1. Epub 2017 Sep 13. Erratum in: Lancet Diabetes Endocrinol. 2017 Nov;5(11):e7. Lancet Diabetes Endocrinol. 2019 May;7(5):e5.

PMID:
28917545
49.

Insulin resistance and cardiovascular outcomes in the ORIGIN trial.

Gerstein HC, Ferrannini E, Riddle MC, Yusuf S; ORIGIN Trial Investigators.

Diabetes Obes Metab. 2018 Mar;20(3):564-570. doi: 10.1111/dom.13112. Epub 2017 Oct 8.

PMID:
28895655
50.

Chronic Kidney Disease, Basal Insulin Glargine, and Health Outcomes in People with Dysglycemia: The ORIGIN Study.

Papademetriou V, Nylen ES, Doumas M, Probstfield J, Mann JFE, Gilbert RE, Gerstein HC.

Am J Med. 2017 Dec;130(12):1465.e27-1465.e39. doi: 10.1016/j.amjmed.2017.05.047. Epub 2017 Aug 31.

PMID:
28842165

Supplemental Content

Loading ...
Support Center